Eric van der Putten is a Partner at Aglaia Oncology Funds. Aglaia invests in oncology drug development companies, focusing on early-stage breakthrough inventions with the potential to transform cancer treatment. The Aglaia team has decades of experience in cancer research and oncology drug development and has built a reputation in starting up biotech companies focused on oncology drug development since 2004. Aglaia defines the strategic directions of its portfolio companies in collaboration with innovators and entrepreneurs, bringing hands-on experience in designing research and development plans, from early screening and animal feasibility studies through clinical studies. Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia, and the team has been involved in the development of more than 100 oncology products.
BioTech, Oncology
Direktes E-Mail-Muster
KI Outreach Agenten Pitch Writer
Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...